• <cite id="15kim"><noscript id="15kim"></noscript></cite><rp id="15kim"></rp>
    <source id="15kim"></source>

    <rp id="15kim"></rp>

    1. <rt id="15kim"></rt>
    2. <tt id="15kim"><noscript id="15kim"></noscript></tt>

        <rp id="15kim"></rp>
        Image by Solera
        March 22, 2018 | By Solera

        Cimzia Label Update Provides New Information For Women Of Childbearing Age

        The FDA approved a label update of UCB’s Cimzia, or certolizumab pegol, to include new data showing a negligible to low risk for drug transfer through placenta and a minimal risk for transfer through breast milk among pregnant women. The drug is currently approved as a treatment for adult patients with active psoriatic arthritis, moderate to severe active rheumatoid arthritis and active ankylosing spondylitis, as well as to ease the symptoms of Crohn’s disease and maintain clinical response in adult patients with moderate to severe active disease who do not respond adequately to conventional therapy.

        Click Here to view the original article at MPR?(login required)


        A smaller focus to make a much larger impact. Our goal is to deliver on every promise we make

        Our Mission

        Learn More